The cost utility of solifenacin in the treatment of overactive bladder

International Urology and Nephrology

Volumn 41, Issue 2, 2009, Pages 293-298

  Hakkaart, Leona ^a   Verboom, Paul ^a   Phillips, Richard ^b   Al, Maiwenn J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Goffin Consultancy Ltd   (United Kingdom)

Author keywords

Cost utility analysis; Markov model; Muscarinic receptor antagonist; Overactive bladder; Urinary incontinence

Indexed keywords

PLACEBO; SOLIFENACIN;

ARTICLE; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAPER; DRUG COST; DRUG EFFICACY; HUMAN; MARKOV MODEL; OVERACTIVE BLADDER; QUALITY ADJUSTED LIFE YEAR; SCORING SYSTEM; SENSITIVITY ANALYSIS; STATISTICAL MODEL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; COST-BENEFIT ANALYSIS; DIAPERS, ADULT; DRUG COSTS; FEMALE; HUMANS; MALE; MARKOV CHAINS; MUSCARINIC ANTAGONISTS; PATIENT COMPLIANCE; QUALITY-ADJUSTED LIFE YEARS; QUINUCLIDINES; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE;

EID: 67349287463     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-008-9448-2     Document Type: Article

References (7)

1. Cardozo L, Castro-Diaz D, Gittelman M et al (2006) Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin. Int Urogynecol J Pelvic Floor Dysfunct 17:512-519. doi: 10.1007/s00192-005-0058-6
2. Hennessey A, Robertson NP, Swingler R et al (1999) Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol 246:1027-1032. doi: 10.1007/s004150050508
3. Johannesson M, O'Conor RM, Kobelt-Nguyen G et al (1997) Willingness to pay for reduced incontinence symptoms. Br J Urol 80:557-562
4. Kobelt G, Jonsson L, Mattiasson A (1998) Cost-effectiveness of new treatments for overactive bladder: The example of tolterodine, a new muscarinic agent: A Markov model. Neurourol Urodyn 17:599-611. doi: 10.1002/(SICI)1520-6777(1998)17:6<599::AID-NAU4>3.0.CO;2-J
5. Milsom I, Abrams P, Cardozo L, Roberts RG et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760-766. doi: 10.1046/ j.1464-410x.2001.02228.x
6. Nabi G, Cody JD, Ellis G, Herbison P et al (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev CD003781
7. Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322-338. doi: 10.1177/ 0272989X9301300409